COMMUNIQUÉS West-GlobeNewswire

RadNet, Inc. to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
07/06/2024
LOS ANGELES, June 07, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07/06/2024
Company announcement - No. 30 / 2024 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 [...]
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07/06/2024
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%). [...]
EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia
07/06/2024
SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has today announced strategic [...]
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
07/06/2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its [...]
Rapport Therapeutics Announces Pricing of Initial Public Offering
07/06/2024
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines [...]
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
07/06/2024
WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful [...]
UPDATED: Public Hearings on Protecting and Improving Local Hospitals: Community members invited to give input
06/06/2024
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- In response to more than 1,200 closures of emergency departments and other local hospital services over the last year, the Ontario Health Coalition (OHC) is holding public [...]
BrightSpring Awards Brighter Futures Scholarship and Hospice Nursing Scholarship to Help Five Louisville Students Pursue Healthcare Careers
06/06/2024
LOUISVILLE, Ky., June 06, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, ("BrightSpring” or “BrightSpring Health Services“) (NASDAQ: BTSG), a leading provider of home and community-based health services for [...]
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
06/06/2024
REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) [...]
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
06/06/2024
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06/06/2024
LAKE FOREST, Ill., June 06, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated [...]
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
06/06/2024
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
06/06/2024
HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be [...]
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period
06/06/2024
NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 [...]
‘Disparate-Impact’ Thinking Is Destroying Medicine, States President of the Association of American Physicians and Surgeons (AAPS)
06/06/2024
TUCSON, Ariz., June 06, 2024 (GLOBE NEWSWIRE) -- Any notion that medicine was immune to the culture shocks in our nation was destroyed by the intersection of the George Floyd response and COVID-era policy, writes [...]
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
06/06/2024
WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically [...]
BioSenic announces 2023 full year results
06/06/2024
PRESS RELEASE - REGULATED INFIRMATION BioSenic stopped the patient recruitment for its Phase 2b ALLOB trial in mid-2023. BioSenic has prepared a global restructuring plan covering the years 2024-2032 and will actively [...]
BioSenic publie ses résultats annuels 2023
06/06/2024
COMMUNIQUÉ DE PRESSE – INFORMATION REGLEMENTEE BioSenic a arrêté le recrutement des patients pour son essai de phase 2b ALLOB à la mi-2023. BioSenic a préparé un plan de restructuration global couvrant les années 2024- [...]

Pages